DexCom, Inc. (DXCM)

FairStock Score: 61/100 — STEADY

Key Financials

Strengths

• Perfect Piotroski F-Score (9/9) demonstrates pristine financial health and quality earnings
• Exceptional ROE of 34.5% with reasonable ROCE of 8.89% shows capital efficiency in a capital-light recurring revenue model
• Strong free cash flow generation ($719.5M) funds growth without excessive leverage (D/E: 0.51)
• Massive addressable market (400M+ diabetics globally) with secular tailwinds from CGM adoption expansion
• Q4 2025 net margin of 21.2% on $1.3B revenue demonstrates pricing power and operational excellence

Concerns

• Valuation is indefensible: 66.5x EV/EBITDA and Graham Number of $10.53 vs. $68.74 price represents negative margin of safety
• High beta of 1.53 indicates volatility—premium valuations on growth stocks compress rapidly in market downturns
• Competitive threats emerging (Medtronic, Abbott, Senseonics) in CGM space could pressure margins and growth rates
• FCF yield of just 0.7% reflects stretched valuation; little room for disappointment without material multiple compression

AI Analysis

DexCom presents a fascinating paradox—a genuinely exceptional business trading at a decidedly un-exceptional price. Let me be direct: this company possesses precisely what Graham and I seek: a durable competitive moat, exceptional returns on capital, and free cash flow generation that cannot be ignored. The business fundamentals are compelling. DexCom's Q4 2025 results show $1.3B in revenue with a 21% net margin—that's manufacturing excellence paired with pricing power. The Piotroski F-Score of 9/9 indicates near-perfect financial health. Most importantly, this is a recurring revenue business in an expanding market. Continuous glucose monitoring addresses a fundamental human need for 400+ million diabetics globally. That's the kind of secular tailwind that separates compounders from commodity operators. The balance sheet is fortress-like: Altman Z-Score of 5.74 signals no bankruptcy risk whatsoever. A 0.51 debt-to-equity ratio is conservative. Free cash flow of $719.5M on a $26.8B market cap yields just 0.7%—this capital generates substantial reinvestment opportunities. However, here's where discipline must override enthusiasm. The valuation is punitive. At $68.74, we're paying 66.5x EV/EBITDA. The P/B of 9.38 and Graham Number of just $10.53 represent a margin of safety of negative 552%—meaning you're paying six times what a value investor's intrinsic value calculation suggests. The 32 P/E ratio isn't unreasonable for a growth company, but combined with the EV/EBITDA multiple, it's stretched. I would eagerly acquire DexCom at $25-30 per share. At $68, I'm watching rather than buying. Quality alone doesn't justify any price.

Bull Case

DexCom's domination of the CGM market positions it to grow at 15-20% annually for a decade as penetration expands globally and reimbursement improves. At these growth rates and margins, the business could sustain higher multiples if execution continues, particularly as Stelo opens the prediabetes market.

Bear Case

A single quarter of disappointing growth or margin compression could trigger a 30-40% revaluation given the valuation premium. Competition and reimbursement pressure could flatten growth rates while rising interest rates make stretched valuations untenable for growth investors.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer